Shares in Roche fell on Thursday after an early-stage obesity pill candidate that carries high market hopes was linked to a high rate of temporary side effects in its initial test phase on humans.

Roche Obesity Pill Study: What Are the Side Effects of the Weight-Loss Drug?

02:24am, Thursday, 12'th Sep 2024

A study of a closely-watched experimental Roche obesity pill has been tied to side effects, including nausea and vomiting, in a small study. The results raise questions for investors evaluating whethe

Why Roche Holdings Stock Withered on Wednesday

06:49pm, Wednesday, 11'th Sep 2024

The storied European pharmaceutical is forging ahead in its efforts to develop a weight loss treatment. Recent news from the lab about the medication is not encouraging, however.

Roche says early-stage obesity pill results were based on just six patients

11:50am, Wednesday, 11'th Sep 2024

Roche said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its shares in July were based on just six patients, underscoring the uncertain

Roche: Why I'm Not Concerned About Slight Sell-Off On Weight Loss Drug Safety Data

11:06am, Wednesday, 11'th Sep 2024

Roche stock has risen 22% since May due to promising GLP-1 agonist drug candidates, despite recent setbacks with CT-388's side effects. Roche's GLP-1 pipeline includes CT-388, CT-996 and CT-868, aimin

Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation

10:00am, Tuesday, 10'th Sep 2024

Basel, 10 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the opening of its new Pharma Research and Early Development (pRED) Center at its global headquarters in Basel, Switzerlan

Lunit Joins Roche's Digital Pathology Open Environment to Advance Cancer Biomarker Testing

09:00am, Monday, 09'th Sep 2024

Lunit's AI-powered biomarker, Lunit SCOPE PD-L1 TPS, integrates into Roche's navify® Digital Pathology platform to enhance precision medicine and improve cancer biomarker testing SEOUL, South Korea ,

The Zacks Analyst Blog Amazon, Roche, GE Aerospace, Canterbury Park and NVE

05:15am, Monday, 09'th Sep 2024

Amazon, Roche, GE Aerospace, Canterbury Park and NVE are included in this Analyst Blog.

Stratipath and Roche Join Forces to Help Expand Access to AI-Powered Precision Diagnostics

04:05am, Monday, 09'th Sep 2024

Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, is thrilled to announce a collaboration with Roche, the world's largest biotechnology company and the

Roche advances AI-driven cancer diagnostics by expanding its digital pathology open environment

01:00am, Monday, 09'th Sep 2024

The Roche Digital Pathology Open Environment brings together a wide array of innovative AI-based pathology tools to help clinicians improve patient care and expand personalised healthcare. Roche is no

3 Dividend Stocks for September 2024

11:00am, Sunday, 08'th Sep 2024

#Morningstar  #KHCStock #DividendStocks We look at the dividend prospects of two narrow-moat companies and a wide-moat biopharma firm. 00:00 Introduction 00:10 Kinder Morgan KMI 00:50 Kraft Heinz KH

Roche's fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis

02:00am, Wednesday, 04'th Sep 2024

Basel, 04 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new 48-week data for the investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib from the Phase II FENopta open

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by